Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups

The FDA approval of immune checkpoint inhibitors for cancers with tumor mutation burden (TMB) of at least 10 mut/Mb is postulated to reduce healthcare disparities by broadly expanding treatment eligibility. In a cohort of 39,400 patients with available genomic and race data, black and Asian patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsiehchen, David, Espinoza, Magdalena, Valero, Cristina, Ahn, Chul, Morris, Luc G T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Hypothesis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603286/
https://www.ncbi.nlm.nih.gov/pubmed/34795008
http://dx.doi.org/10.1136/jitc-2021-003683

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603286/
https://www.ncbi.nlm.nih.gov/pubmed/34795008
http://dx.doi.org/10.1136/jitc-2021-003683

Ejemplares similares